相关实验视频

Updated: Feb 19, 2026

Guide Wire Assisted Catheterization and Colored Dye Injection for Vascular Mapping of Monochorionic Twin Placentas

Guide Wire Assisted Catheterization and Colored Dye Injection for Vascular Mapping of Monochorionic Twin Placentas

Published on: September 5, 2011

在二双胞胎怀孕中,长期的印米他辛治疗和宫稳定

Mevlut Bucak¹, Karl Seif¹, Katherine Goetzinger¹

¹Department of Obstetrics, Gynecology and Reproductive Science, University of Maryland Medical Center, Baltimore, MD, USA.

The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians

|February 17, 2026

概括

长期的印米他辛治疗 (LIT) 在81.5%的双胞胎怀孕中稳定了子宫,其中DCDA怀孕的双胞胎怀孕的子宫短. 这种方法还增加了分娩时的妊娠年龄,这表明对高风险怀孕的潜在益处.

科学领域:

孕产妇和胎儿医学孕产妇和胎儿医学
周围生理学周围生理学
产科产科产科产科产科

背景情况:

双胞胎怀孕的迪科里奥尼-迪亚米诺斯 (DCDA) 双胞胎怀孕的子宫短处于早产的风险增加.
宫长度是怀孕活力和早产风险的关键指标.

研究的目的:

评估长期印梅他辛治疗 (LIT) 在DCDA双胞胎怀孕中稳定子宫长度的疗效,这些怀孕的子宫短.
评估LIT对高风险产妇群体在分娩时妊娠年龄的影响.

主要方法:

一个回顾性队列研究,涉及54个DCDA双胞胎怀孕,子宫长度≤25毫米.
长期的印梅他辛治疗 (LIT) 在妊娠18-26周之间进行.
宫稳定是通过将观察到的最后一个宫长度 (O_LCL) 与基于生理缩短率的预期长度 (E_CL) 进行比较来定义的.

主要成果:

用LIT治疗的81.5%病例实现了宫稳定.
最后观察到的宫长度明显大于预期的长度 (p < .001).
与非稳定组 (30.8周) 相比,稳定组 (34.6周) 的妊娠年龄在分娩时显著更高.

结论:

长期的印梅他辛治疗 (LIT) 与DCDA双胞胎怀孕的宫稳定有关,而宫短.
这一发现表明LIT可能是一个可行的策略,在高风险双胞胎怀孕中延长妊娠期.
需要进一步的前性研究来证实这些产生假设的结果.

关键词:

双胞胎怀孕双胞胎怀孕是什么意思宫的长度宫的长度印度甲素 (Indomethacin) 是一种过早出生过早出生短的子宫短的子宫.

更多相关视频

Accurate and Simple Evaluation of Vascular Anastomoses in Monochorionic Placenta using Colored Dye

Accurate and Simple Evaluation of Vascular Anastomoses in Monochorionic Placenta using Colored Dye

Published on: September 5, 2011

Model Surgical Training: Skills Acquisition in Fetoscopic Laser Photocoagulation of Monochorionic Diamniotic Twin Placenta Using Realistic Simulators

Model Surgical Training: Skills Acquisition in Fetoscopic Laser Photocoagulation of Monochorionic Diamniotic Twin Placenta Using Realistic Simulators

Published on: March 21, 2018

相关概念视频

Intrauterine Drug Delivery Systems

Intrauterine Drug Delivery Systems

Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...